CD274 and non-small cell lung carcinoma: However, in our patient collective, the vast majority received chemotherapy-ICI combination treatment, which reflects the current clinical practice in a considerably larger patient population as compared to the discussed evaluations of mono-ICI in NSCLC with PD-L1 ≥ 50%.